Tourmaline Bio to Present at the Jefferies Global Healthcare Conference
Tourmaline Bio (NASDAQ: TRML), a late-stage clinical biotechnology company, announced that its CEO, Sandeep Kulkarni, will present at the Jefferies Global Healthcare Conference in New York. The presentation is scheduled for Thursday, June 6, 2024, at 2:30 pm ET. A live webcast and replay will be available on the Tourmaline Bio website.
- CEO Sandeep Kulkarni will present at a high-profile investor conference, which can enhance visibility and attract new investors.
- The live webcast and replay availability provide opportunities for wider audience engagement beyond the conference attendees.
- The press release lacks specific details on financial performance or clinical trial data, providing actionable information for investors.
- There is no mention of new product launches, partnerships, or significant corporate developments, which may be seen as a lack of business progress.
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, CEO, is expected to participate in the following investor conference:
Jefferies Global Healthcare Conference, New York
Corporate Presentation
Thursday, June 6, 2024 at 2:30 pm ET
A live webcast and replay will be posted under "Events and Presentations" in the News & Investors section of the Tourmaline Bio website at https://ir.tourmalinebio.com.
About Tourmaline Bio, Inc.
Tourmaline is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases. Tourmaline’s lead asset is TOUR006.
About TOUR006
TOUR006 is a long-acting, fully human, anti-IL-6 monoclonal antibody with best-in-class potential and differentiated properties, including a naturally long half-life, low immunogenicity, and high binding affinity to IL-6. TOUR006 has been previously studied in 448 participants, including patients with autoimmune disorders, across six completed clinical trials. Tourmaline is developing TOUR006 in TED and ASCVD as its first two indications, with additional diseases under consideration.
Contact:
Meru Advisors
Lee M. Stern
lstern@meruadvisors.com
FAQ
When will Tourmaline Bio present at the Jefferies Global Healthcare Conference?
Who will represent Tourmaline Bio at the Jefferies Global Healthcare Conference?
Where can I watch the Tourmaline Bio presentation at the Jefferies Global Healthcare Conference?